AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32732104 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycle-based exercise
Number of subjects: 99
Study 32732104 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 99
Study 34627829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg.kg‐1 dexmedetomidine (DEX 0.5 group)
Number of subjects: 130
Study 34627829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg.kg‐1 dexmedetomidine (DEX 1 group)
Number of subjects: 130
Study 32306213 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand PrEP during the Open-Label Extension (OLE) phase
Number of subjects: 0
Study 33935153 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy-guided movement supplemented with virtual reality
Number of subjects: 41
Study 33935153 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy-guided movement alone without virtual reality
Number of subjects: 41
Study 34678758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg of 0.1% E2 gel per day
Number of subjects: 78
Study 34678758 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 78
Study 32749918 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐Turmactive® (water‐soluble TEs and insoluble curcuminoids)
Number of subjects: 68
Study 32749918 — intervention group
Group type: COMPARATOR
Intervention: Brewer's yeast (placebo)
Number of subjects: 68
Study 32749918 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐Turmactive®
Number of subjects: 68
Study 35302455 — intervention group
Group type: EXPERIMENTAL
Intervention: Taboo group (interactive gaming, education-based strategy)
Number of subjects: 26
Study 35302455 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling group (education-based strategy using non-fictional and fictional case scenarios)
Number of subjects: 26
Study 32869592 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of mouse nerve growth factor (mNGF) at various acupoints (0.3-0.5 mL, total 18 µg/2 mL)
Number of subjects: 63
Study 32869592 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of mouse nerve growth factor (mNGF) (18 µg/2 mL)
Number of subjects: 63
Study 32869592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Acupoint and Intramuscular)
Number of subjects: 63
Study 32869592 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of mouse nerve growth factor (mNGF)
Number of subjects: 63
Study 32200649 — intervention group
Group type: EXPERIMENTAL
Intervention: RSE-MA (10 m maximal acceleration, 2.12 m.s‐2)
Number of subjects: 16
Study 32340650 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Selenite (SS) addition (0.3 mg Se/kg DM)
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated Sodium Selenite (CSS) addition (0.1, 0.2 and 0.3 mg Se/kg DM)
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Coated Sodium Selenite (MCSS) addition (0.2 mg Se/kg DM)
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: High Coated Sodium Selenite (HCSS) addition (0.3 mg Se/kg DM)
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Selenite (SS) or Coated Sodium Selenite (CSS) addition
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Selenite (SS), Medium Coated Sodium Selenite (MCSS) and High Coated Sodium Selenite (HCSS)
Number of subjects: 60
Study 32340650 — intervention group
Group type: EXPERIMENTAL
Intervention: High Coated Sodium Selenite (HCSS) addition
Number of subjects: 60
Study 34228834 — intervention group
Group type: EXPERIMENTAL
Intervention: Running-related injuries (RRIs)
Number of subjects: 1929
Study 36375565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT) including oral hygiene instructions, scaling and root planing; and 0.05% Chlorhexidine mouthrinse
Number of subjects: 40
Study 36375565 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment including oral hygiene instructions, supragingival removal of plaque and calculus and 0.05% Chlorhexidine mouthrinse
Number of subjects: 40
Study 34085475 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy
Number of subjects: 92
Study 34085475 — intervention group
Group type: COMPARATOR
Intervention: Sham-auricular point therapy
Number of subjects: 92
Study 34085475 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 92
Study 32169479 — intervention group
Group type: COMPARATOR
Intervention: Coffee (group C)
Number of subjects: 3
Study 32169479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea (group T)
Number of subjects: 3
Study 32169479 — intervention group
Group type: COMPARATOR
Intervention: Tap water (group N)
Number of subjects: 3
Study 35671228 — intervention group
Group type: COMPARATOR
Intervention: 25% HP for 45 minutes (Group A)
Number of subjects: 90
Study 35671228 — intervention group
Group type: COMPARATOR
Intervention: 5% PN for 45 minutes (Group B)
Number of subjects: 90
Study 35671228 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PN and 25% HP for 45 minutes (Group C)
Number of subjects: 90
Study 35671228 — intervention group
Group type: COMPARATOR
Intervention: 3% PN in a 40% HP gel for 45 minutes (Group D)
Number of subjects: 90
Study 32138625 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 2328
Study 32138625 — intervention group
Group type: COMPARATOR
Intervention: Open Abdominal Aneurysm Repair (OAAR)
Number of subjects: 2328
Study 34260092 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 100
Study 34260092 — intervention group
Group type: COMPARATOR
Intervention: Standard patient education
Number of subjects: 100
Study 34260092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 33395931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh source-separated human urine
Number of subjects: 0
Study 33395931 — intervention group
Group type: COMPARATOR
Intervention: Stored source-separated human urine (after 30 days)
Number of subjects: 0
Study 32726727 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based health education program
Number of subjects: 108
Study 32726727 — intervention group
Group type: COMPARATOR
Intervention: Routine postpartum home visits (Control)
Number of subjects: 108
Study 35272093 — intervention group
Group type: EXPERIMENTAL
Intervention: Early gestational diabetes mellitus screening at 14 to 20 weeks of gestation
Number of subjects: 119
Study 35272093 — intervention group
Group type: COMPARATOR
Intervention: Gestational diabetes mellitus diagnosed with routine screening at 24 to 28 weeks of gestation
Number of subjects: 119
Study 34839804 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat video
Number of subjects: 207
Study 34839804 — intervention group
Group type: COMPARATOR
Intervention: Low-threat video
Number of subjects: 207
Study 35913665 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied examples of deliberate reflection and explained the procedure to a fictitious peer on video
Number of subjects: 56
Study 35913665 — intervention group
Group type: COMPARATOR
Intervention: Solved cases without reflection (control)
Number of subjects: 56
Study 32772451 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder prompt to seek further medical attention
Number of subjects: 266
Study 32772451 — intervention group
Group type: COMPARATOR
Intervention: No reminder prompt (control group)
Number of subjects: 266
Study 32449942 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 16 mg/d, T.I.D.
Number of subjects: 40
Study 32449942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35984033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone wax application
Number of subjects: 152
Study 34125586 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000-word consent form
Number of subjects: 240
Study 34125586 — intervention group
Group type: COMPARATOR
Intervention: 6,000-word consent form (control)
Number of subjects: 240
Study 32212983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg orally once daily
Number of subjects: 417
Study 32212983 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme A 400 mg orally once daily
Number of subjects: 417
Study 33839766 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker intervention (Polar Loop 2) worn daily for 12 months
Number of subjects: 231
Study 33839766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity tracker)
Number of subjects: 231
Study 33839766 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker intervention (Polar Loop 2)
Number of subjects: 231
Study 35254948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 1949
Study 35254948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 1949
Study 35254948 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (both doses)
Number of subjects: 1949
Study 35254948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1949
Study 34029163 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (QHCl) 10 µmol/kg, intragastrically (IG)
Number of subjects: 14
Study 34029163 — intervention group
Group type: EXPERIMENTAL
Intervention: Denatonium benzoate (DB) 1 µmol/kg, intragastrically (IG)
Number of subjects: 14
Study 34029163 — intervention group
Group type: COMPARATOR
Intervention: Placebo, intragastrically (IG)
Number of subjects: 14
Study 34029163 — intervention group
Group type: EXPERIMENTAL
Intervention: Denatonium benzoate (DB) 1 µmol/kg, intraduodenally (ID)
Number of subjects: 14
Study 34029163 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (QHCl) 10 µmol/kg, intraduodenally (ID)
Number of subjects: 14
Study 34029163 — intervention group
Group type: COMPARATOR
Intervention: Placebo, intraduodenally (ID)
Number of subjects: 14
Study 32170552 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 623
Study 32170552 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 623
Study 36270271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided axillary vein access (USAA)
Number of subjects: 100
Study 36270271 — intervention group
Group type: COMPARATOR
Intervention: Conventional venous access techniques
Number of subjects: 100
Study 36270271 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced USAA implanters
Number of subjects: 100
Study 36270271 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced USAA implanter
Number of subjects: 100
Study 36270271 — intervention group
Group type: EXPERIMENTAL
Intervention: USAA
Number of subjects: 100
Study 32663066 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally-enabled rehabilitation using eight digital devices (virtual reality videogames, activity monitors, handheld computer devices) for 6 months.
Number of subjects: 144
Study 32663066 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy contact every 1-2 weeks using a health coaching approach.
Number of subjects: 144
Study 32663066 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for device use categorized into initial set-up and instruction (27%), education and training (31%), maintenance (23%), and trouble-shooting (19%).
Number of subjects: 144
Study 35962959 — intervention group
Group type: EXPERIMENTAL
Intervention: Language style matching (LSM)
Number of subjects: 25
Study 34382947 — intervention group
Group type: EXPERIMENTAL
Intervention: AXA1125 24 g
Number of subjects: 102
Study 34382947 — intervention group
Group type: EXPERIMENTAL
Intervention: AXA1957 20.3 g
Number of subjects: 102
Study 34382947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 32469946 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-joint training (MJ)
Number of subjects: 53
Study 32469946 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-joint training (SJ)
Number of subjects: 53
Study 32469946 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 53
Study 36273334 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency stimulation on bilateral hemisphere (5 Hz rTMS)
Number of subjects: 45
Study 36273334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high frequency stimulation on affected hemisphere and low frequency stimulation on unaffected hemisphere (5 Hz rTMS on unaffected, 1 Hz rTMS on affected)
Number of subjects: 45
Study 36273334 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 45
Study 36273334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high frequency group
Number of subjects: 45
Study 36273334 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low group
Number of subjects: 45
Study 36273334 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 45
Study 33581097 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for PH, primarily phosphodiesterase‐5 inhibitors
Number of subjects: 375
Study 33581097 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for PH
Number of subjects: 375
Study 33581097 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for PH in severe PH‐COPD
Number of subjects: 375
Study 33581097 — intervention group
Group type: COMPARATOR
Intervention: PH‐COPD
Number of subjects: 375
Study 32836188 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% FiO2
Number of subjects: 252
Study 32836188 — intervention group
Group type: COMPARATOR
Intervention: 80% FiO2
Number of subjects: 252
Study 33858462 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC1 (high intensity approach)
Number of subjects: 389
Study 33858462 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC2 (low intensity approach)
Number of subjects: 389
Study 33858462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups
Number of subjects: 389
Study 33858462 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 389
Study 33858462 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC1 (high intensity approach) among those trying to conceive
Number of subjects: 389
Study 33858462 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC2 (low intensity approach) among those trying to conceive
Number of subjects: 389
Study 33858462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention arms among those trying to conceive
Number of subjects: 389
Study 33858462 — intervention group
Group type: COMPARATOR
Intervention: Usual care among those trying to conceive
Number of subjects: 389
Study 33029668 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit vessel only percutaneous coronary intervention (CO-PCI)
Number of subjects: 0
Study 33029668 — intervention group
Group type: COMPARATOR
Intervention: Immediate multivessel PCI (MV-PCI)
Number of subjects: 0
Study 34787046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (5 Hz) applied over the left dorsolateral prefrontal cortex (DLPFC) for two weeks
Number of subjects: 60
Study 34787046 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS for two weeks
Number of subjects: 60
Study 34535716 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/day)
Number of subjects: 54
Study 34535716 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 34535716 — intervention group
Group type: EXPERIMENTAL
Intervention: THP-1 cells
Number of subjects: 54
Study 34574482 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 155
Study 34574482 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 155
Study 33209019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (10 g, two times per day for 14 days)
Number of subjects: 378
Study 33209019 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 378
Study 35445748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine (0.03 mg/kg)
Number of subjects: 5
Study 35445748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (0.03 mg/kg)
Number of subjects: 5
Study 35445748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal buprenorphine (0.03 mg/kg)
Number of subjects: 5
Study 33984807 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Attention Bias Modification (ABM)
Number of subjects: 301
Study 33984807 — intervention group
Group type: COMPARATOR
Intervention: Placebo Attention Bias Modification (ABM)
Number of subjects: 301
Study 32691499 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 32691499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33806529 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg every night for six weeks
Number of subjects: 38
Study 33806529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 35472193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (32 international units)
Number of subjects: 160
Study 35472193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 35472193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Number of subjects: 160
Study 33499711 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (15 minutes) before vaccination
Number of subjects: 57
Study 33499711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 57
Study 35641151 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 0
Study 32553118 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus berzosertib (210 mg/m2 on day 2 and day 9 of a 21-day cycle)
Number of subjects: 70
Study 32553118 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m2 on day 1 and day 8 of a 21-day cycle)
Number of subjects: 70
Study 35076933 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening at age 45
Number of subjects: 46642
Study 35076933 — intervention group
Group type: COMPARATOR
Intervention: Digital rectal examination (DRE) with delayed PSA screening at age 50
Number of subjects: 46642
Study 32050792 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy combined with psychological intervention (Cognitive behavioral therapy)
Number of subjects: 60
Study 32050792 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy only (Control group)
Number of subjects: 60
Study 34294416 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa plus chemotherapy (carboplatin and gemcitabine)
Number of subjects: 71
Study 34294416 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 71
Study 35880079 — intervention group
Group type: EXPERIMENTAL
Intervention: S.boulardii monotherapy for 2 weeks followed by bismuth quadruple therapy if H. pylori positive after 4 weeks
Number of subjects: 100
Study 35880079 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 6 weeks followed by bismuth quadruple therapy if H. pylori positive
Number of subjects: 100
Study 35880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Total treatment effect of S.boulardii and bismuth quadruple therapy
Number of subjects: 100
Study 35880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of S.boulardii
Number of subjects: 100
Study 35880079 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 100
Study 33358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine stair climbing test (9SCT)
Number of subjects: 18
Study 33358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest expansion parameters
Number of subjects: 18
Study 33358415 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional capacity (6MWT, 10mWT)
Number of subjects: 18
Study 35694706 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE‐MRI
Number of subjects: 124
Study 35694706 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRI (Control)
Number of subjects: 124
Study 32593555 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief oral information and a leaflet on advanced directives (AD) provided by General Practitioners (GPs)
Number of subjects: 332
Study 32593555 — intervention group
Group type: COMPARATOR
Intervention: Control group received brief information about the study's purpose
Number of subjects: 332
Study 32409324 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 92
Study 32409324 — intervention group
Group type: COMPARATOR
Intervention: CYC
Number of subjects: 92
Study 35402445 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF‐aspiration group (Group A) received spinal anesthesia with 10 mg of hyperbaric 0.5% bupivacaine with aspiration of 0.2 ml of CSF.
Number of subjects: 60
Study 35402445 — intervention group
Group type: COMPARATOR
Intervention: No‐CSF‐aspiration group (Group B) received only 10 mg of 0.5% hyperbaric bupivacaine.
Number of subjects: 60
Study 32390454 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 73
Study 32390454 — intervention group
Group type: COMPARATOR
Intervention: non-efavirenz regimens or no antiretroviral therapy
Number of subjects: 73
Study 32390454 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir diphosphate (TFVdp)
Number of subjects: 73
Study 32390454 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir
Number of subjects: 73
Study 37430016 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 68
Study 37430016 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 68
Study 34495173 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification by Degree of Clinical Severity and Abandonment Risk of Tuberculosis Treatment (SRTB)
Number of subjects: 432
Study 34495173 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 432
Study 32267646 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) technique
Number of subjects: 0
Study 32267646 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard ALND without ARM)
Number of subjects: 0